Literature DB >> 21934731

Research progress on interleukin-33 and its roles in the central nervous system.

Ping Han1, Wen-Li Mi, Yan-Qing Wang.   

Abstract

Interleukin-33 (IL-33), a newly recognized IL-1 family member, is expressed by various tissues and cells. Since it can combine with chromosomes, IL-33 is regarded as an intracellular transcription repressor. Upon proinflammatory stimulation, it is released as an extracellular cytokine to function as an alarmin to dangerous signals. The IL-33 receptor is a heterodimer complex composed of ST2 and the IL-1 receptor accessory protein, the latter being conserved in other IL-1 family members. The IL-33/ST2 signaling pathway plays critical roles in inflammatory and immune diseases, as well as in central nervous system (CNS) diseases. Recently, there has been an increasing focus on IL-33, particularly on its production and functions in the CNS. The present review mainly focuses on progress in research on IL-33, especially its roles in the CNS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21934731      PMCID: PMC5560310          DOI: 10.1007/s12264-011-1025-5

Source DB:  PubMed          Journal:  Neurosci Bull        ISSN: 1995-8218            Impact factor:   5.203


  50 in total

1.  IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex.

Authors:  Alissa A Chackerian; Elizabeth R Oldham; Erin E Murphy; Jochen Schmitz; Stefan Pflanz; Robert A Kastelein
Journal:  J Immunol       Date:  2007-08-15       Impact factor: 5.422

2.  Elevation of ST2 protein levels in cerebrospinal fluid following subarachnoid hemorrhage.

Authors:  M Kanda; H Ohto-Ozaki; K Kuroiwa; S Tominaga; E Watanabe; H Iwahana
Journal:  Acta Neurol Scand       Date:  2006-05       Impact factor: 3.209

3.  Production and functions of IL-33 in the central nervous system.

Authors:  Satoko Yasuoka; Jun Kawanokuchi; Bijay Parajuli; Shijie Jin; Yukiko Doi; Mariko Noda; Yoshifumi Sonobe; Hideyuki Takeuchi; Tetsuya Mizuno; Akio Suzumura
Journal:  Brain Res       Date:  2011-02-22       Impact factor: 3.252

4.  Mature interleukin-33 is produced by calpain-mediated cleavage in vivo.

Authors:  Morisada Hayakawa; Hiroko Hayakawa; Yasushi Matsuyama; Hiroyuki Tamemoto; Hitoaki Okazaki; Shin-ichi Tominaga
Journal:  Biochem Biophys Res Commun       Date:  2009-07-09       Impact factor: 3.575

5.  The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33.

Authors:  Gaby Palmer; Brian P Lipsky; Molly D Smithgall; David Meininger; Sophia Siu; Dominique Talabot-Ayer; Cem Gabay; Dirk E Smith
Journal:  Cytokine       Date:  2008-05-02       Impact factor: 3.861

6.  Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation.

Authors:  Axel M Küchler; Jürgen Pollheimer; Johanna Balogh; Jon Sponheim; Linda Manley; Dag R Sorensen; Paula M De Angelis; Helge Scott; Guttorm Haraldsen
Journal:  Am J Pathol       Date:  2008-09-11       Impact factor: 4.307

Review 7.  TIR8/SIGIRR: an IL-1R/TLR family member with regulatory functions in inflammation and T cell polarization.

Authors:  Cecilia Garlanda; Hans-Joachim Anders; Alberto Mantovani
Journal:  Trends Immunol       Date:  2009-08-21       Impact factor: 16.687

8.  IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells.

Authors:  Shafaqat Ali; Michael Huber; Christian Kollewe; Stephan C Bischoff; Werner Falk; Michael U Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-14       Impact factor: 11.205

9.  Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis.

Authors:  Gaby Palmer; Dominique Talabot-Ayer; Céline Lamacchia; Dean Toy; Christian A Seemayer; Sébastien Viatte; Axel Finckh; Dirk E Smith; Cem Gabay
Journal:  Arthritis Rheum       Date:  2009-03

10.  Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)- but not Th1-driven immunopathology.

Authors:  G Walzl; S Matthews; S Kendall; J C Gutierrez-Ramos; A J Coyle; P J Openshaw; T Hussell
Journal:  J Exp Med       Date:  2001-04-02       Impact factor: 14.307

View more
  17 in total

Review 1.  Innate immunity in the central nervous system.

Authors:  Richard M Ransohoff; Melissa A Brown
Journal:  J Clin Invest       Date:  2012-04-02       Impact factor: 14.808

2.  Potential therapeutic targets for intracerebral hemorrhage-associated inflammation: An update.

Authors:  Honglei Ren; Ranran Han; Xuemei Chen; Xi Liu; Jieru Wan; Limin Wang; Xiuli Yang; Jian Wang
Journal:  J Cereb Blood Flow Metab       Date:  2020-05-19       Impact factor: 6.200

3.  Alzheimer's disease: evidence for the expression of interleukin-33 and its receptor ST2 in the brain.

Authors:  Zhi Xiong; Ramasamy Thangavel; Duraisamy Kempuraj; Evert Yang; Smita Zaheer; Asgar Zaheer
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

4.  IL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline.

Authors:  Amy K Y Fu; Kwok-Wang Hung; Michael Y F Yuen; Xiaopu Zhou; Deejay S Y Mak; Ivy C W Chan; Tom H Cheung; Baorong Zhang; Wing-Yu Fu; Foo Y Liew; Nancy Y Ip
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-18       Impact factor: 11.205

5.  Glia maturation factor induces interleukin-33 release from astrocytes: implications for neurodegenerative diseases.

Authors:  Duraisamy Kempuraj; Mohammad Moshahid Khan; Ramasamy Thangavel; Zhi Xiong; Evert Yang; Asgar Zaheer
Journal:  J Neuroimmune Pharmacol       Date:  2013-02-10       Impact factor: 4.147

6.  Inhibition of Spinal Interleukin-33 Attenuates Peripheral Inflammation and Hyperalgesia in Experimental Arthritis.

Authors:  Si-Jian Huang; Lu-Yao Zhou; Fei Ren; Wang-Yuan Zou; Jian-Qin Yan; Jian-Gang Luo
Journal:  Mol Neurobiol       Date:  2022-01-22       Impact factor: 5.590

7.  Inhibition of Spinal Interlukin-33/ST2 Signaling and Downstream ERK and JNK Pathways in Electroacupuncture Analgesia in Formalin Mice.

Authors:  Ping Han; Shenbin Liu; Mengting Zhang; Jing Zhao; Yanqing Wang; Gencheng Wu; Wenli Mi
Journal:  PLoS One       Date:  2015-06-12       Impact factor: 3.240

8.  Role of IL-33 and its receptor in T cell-mediated autoimmune diseases.

Authors:  Qing Zhao; Guangjie Chen
Journal:  Biomed Res Int       Date:  2014-06-16       Impact factor: 3.411

9.  Role of IL-33 and ST2 signalling pathway in multiple sclerosis: expression by oligodendrocytes and inhibition of myelination in central nervous system.

Authors:  Debbie Allan; Karen J Fairlie-Clarke; Christina Elliott; Cornelia Schuh; Susan C Barnett; Hans Lassmann; Christopher Linnington; Hui-Rong Jiang
Journal:  Acta Neuropathol Commun       Date:  2016-07-26       Impact factor: 7.801

10.  Serum IL-33 Is a Novel Diagnostic and Prognostic Biomarker in Acute Ischemic Stroke.

Authors:  Li Qian; Lin Yuanshao; Huang Wensi; Zhou Yulei; Chen Xiaoli; Wang Brian; Zhang Wanli; Cai Zhengyi; Xue Jie; Zhang Wenhui; Yu Tieer; Wang Hong; He Jincai; Jin Kunlin; Shao Bei
Journal:  Aging Dis       Date:  2016-10-01       Impact factor: 6.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.